Citations: Loteprednol Etabonate 0.5%/Tobramycin 0.3% Compared with Dexamethasone 0.1%/Tobramycin 0.3% for the Treatment of Blepharitis

3,155

Views

CrossRef citations to date

Altmetric

Citations (4)

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Timothy L. Comstock & John D. Sheppard. (2018) Loteprednol etabonate for inflammatory conditions of the anterior segment of the eye: twenty years of clinical experience with a retrometabolically designed corticosteroid. Expert Opinion on Pharmacotherapy 19:4, pages 337-353.
Read now

Articles from other publishers (3)

Francis S. Mah & Paul M. Karpecki. (2021) Review of Loteprednol Etabonate 0.5%/Tobramycin 0.3% in the Treatment of Blepharokeratoconjunctivitis. Ophthalmology and Therapy 10:4, pages 859-875.
Crossref

Lu Zhao, Ya-jie Sun & Zhi-qiang Pan. (2021) Topical Steroids and Antibiotics for Adult Blepharokeratoconjunctivitis (BKC): A Meta-Analysis of Randomized Clinical Trials. Journal of Ophthalmology 2021, pages 1-9.
Crossref

Mohammud G Musleh, Desta Bokre & Annegret H Dahlmann-Noor. (2019) Risk of intraocular pressure elevation after topical steroids in children and adults: A systematic review. European Journal of Ophthalmology 30:5, pages 856-866.
Crossref

Loteprednol Etabonate 0.5%/Tobramycin 0.3% Compared with Dexamethasone 0.1%/Tobramycin 0.3% for the Treatment of Blepharitis

Articles from other publishers (3)

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Loteprednol Etabonate 0.5%/Tobramycin 0.3% Compared with Dexamethasone 0.1%/Tobramycin 0.3% for the Treatment of Blepharitis

Citations (4)

Read on this site (1)

Articles from other publishers (3)

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date